title: Nerve sparing retroperitoneal lymphadenectomy in clinical stage I, low stage II and after chemotherapy in stage III nonseminomatous testicular cancer.
abstract: Future efforts should focus on finding more sensitive and specific noninvasive means to reach the accuracy of pathology staging. Currently, we believe that a nerve sparing retroperitoneal lymphadenectomy has therapeutic and prognostic value and it will guide the clinician for the necessity of further treatment.
authors.affiliation: University of Maryland, School of Medicine, Baltimore 21201.
authors.forename: N
authors.initials: N
authors.lastname: Javadpour
mesh_terms: D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D007172:Erectile Dysfunction / Q000517:prevention & control; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods*; D008297:Male; D009367:Neoplasm Staging; D009434:Neural Pathways / Q000601:surgery; D011379:Prognosis; D011446:Prospective Studies; D011897:Random Allocation; D012187:Retroperitoneal Space / Q000601:surgery*; D013724:Teratoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*
chemical_list: D002945:Cisplatin